IDEXX Laboratories, Inc. (IDXX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

IDEXX Laboratories, Inc. (IDXX) Healthcare & Pipeline Overview

IDEXX Laboratories, Inc. (IDXX) is a global leader in veterinary diagnostics and water quality, providing innovative solutions for companion animal health, livestock management, and water safety. With a focus on advanced technology and comprehensive services, IDEXX serves a diverse customer base through its CAG, Water Quality Products, and LPD segments.

What Is the Investment Thesis for IDXX?

IDEXX Laboratories presents a notable research candidate based on its leading position in the growing veterinary diagnostics market. The increasing pet ownership and rising spending on animal healthcare are key drivers for IDEXX's revenue growth. The company's strong financial performance, with a profit margin of 24.6% and a gross margin of 62.1%, indicates efficient operations and pricing power. A free cash flow of $0.82 billion provides financial flexibility for strategic investments and acquisitions. Upcoming catalysts include continued expansion of its reference laboratory network and the introduction of new diagnostic products. Potential risks include increased competition and economic downturns affecting pet owner spending. The company's high beta of 1.72 suggests higher volatility compared to the market.

Based on FMP financials and quantitative analysis

IDXX Key Highlights

• Market capitalization of $43.0B reflects investor confidence in IDEXX's market leadership and growth potential.
• P/E ratio of 38.5 indicates a premium valuation, reflecting expectations of future earnings growth.
• Profit margin of 24.6% demonstrates strong profitability and efficient cost management.
• Gross margin of 62.1% highlights the value-added nature of IDEXX's products and services.
• Free cash flow of $0.82 billion provides financial flexibility for strategic investments and shareholder returns.

Who Are IDXX's Competitors?

IDXX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IDXX's Key Strengths?

• Leading market share in veterinary diagnostics.
• Strong brand recognition and customer loyalty.
• Extensive global distribution network.
• Innovative product development capabilities.

What Are IDXX's Weaknesses?

• High reliance on the companion animal market.
• Exposure to economic cycles affecting pet owner spending.
• Dependence on third-party distributors in some regions.
• Potential for product liability claims.

What Could Drive IDXX Stock Higher?

• Launch of new diagnostic products for companion animals.
• Expansion of the reference laboratory network.
• Increasing pet ownership and spending on animal healthcare.
• Growing demand for water quality testing.

What Are the Key Risks for IDXX?

• Rich valuation — a P/E of 38.5 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Increased competition from established and emerging players.
• Economic downturns affecting pet owner spending.
• Changes in regulatory requirements for diagnostic products.
• Product liability claims.
• Dependence on third-party distributors in some regions.

What Are the Growth Opportunities for IDXX?

• Expansion of Reference Laboratory Network: IDEXX can further expand its global network of reference laboratories, offering advanced diagnostic testing services to veterinarians. This expansion can drive revenue growth by increasing access to specialized tests and improving turnaround times. The global veterinary reference laboratory market is estimated to be worth several billion dollars, providing a significant growth opportunity for IDEXX. Timeline: Ongoing.
• New Product Development: IDEXX can continue to invest in research and development to introduce new diagnostic products and services for companion animals, livestock, and water quality testing. This includes developing more accurate and efficient diagnostic tests, as well as expanding into new therapeutic areas. The market for innovative diagnostic solutions is constantly evolving, creating opportunities for IDEXX to maintain its competitive edge. Timeline: Ongoing.
• Strategic Acquisitions: IDEXX can pursue strategic acquisitions to expand its product portfolio, geographic reach, and technological capabilities. This includes acquiring companies with complementary technologies or market positions. The animal health and diagnostics industry is consolidating, creating opportunities for IDEXX to acquire valuable assets and strengthen its market position. Timeline: Ongoing.
• Penetration of Emerging Markets: IDEXX can focus on expanding its presence in emerging markets, where pet ownership and spending on animal healthcare are growing rapidly. This includes establishing sales and marketing operations, as well as partnering with local distributors. The emerging markets offer significant growth potential for IDEXX, as these markets are underserved by existing diagnostic providers. Timeline: Ongoing.
• Digital Solutions and Software: IDEXX can further develop and integrate its digital solutions and practice management software to enhance the customer experience and improve operational efficiency for veterinary clinics. This includes offering cloud-based solutions, mobile apps, and data analytics tools. The increasing adoption of digital technologies in veterinary practices creates opportunities for IDEXX to provide value-added services and strengthen customer relationships. Timeline: Ongoing.

What Opportunities Does IDXX Have?

• Expansion into emerging markets with growing pet populations.
• Development of new diagnostic tests for emerging diseases.
• Acquisition of complementary businesses to expand product portfolio.
• Increased adoption of digital technologies in veterinary practices.

What Threats Does IDXX Face?

• Increased competition from established and emerging players.
• Changes in regulatory requirements for diagnostic products.
• Economic downturns affecting pet owner spending.
• Potential for product recalls or safety issues.

What Are IDXX's Competitive Advantages?

• Strong brand reputation and customer loyalty.
• Extensive global network of reference laboratories.
• Comprehensive product portfolio and integrated solutions.
• Proprietary diagnostic technologies and intellectual property.

What Does IDXX Do?

IDEXX Laboratories, Inc., founded in 1983 and headquartered in Westbrook, Maine, has evolved into a global leader in animal health and water quality diagnostics. The company's initial focus was on developing innovative diagnostic tests for livestock, but it quickly expanded into the companion animal market, recognizing the growing demand for advanced veterinary care. Over the years, IDEXX has built a comprehensive portfolio of products and services, including point-of-care veterinary diagnostic instruments, reference laboratory services, and practice management software. Its Companion Animal Group (CAG) segment is the largest, offering a wide range of diagnostic solutions for veterinarians, including in-clinic analyzers, rapid assay test kits, and reference laboratory services. The Water Quality Products segment provides tests for detecting microbiological contaminants in water, ensuring water safety for municipalities and private users. The Livestock, Poultry, and Dairy (LPD) segment offers diagnostic and health-monitoring products for livestock producers. IDEXX's geographic reach extends across North America, Europe, and Asia-Pacific, with a strong presence in both developed and emerging markets. The company's commitment to innovation and customer service has solidified its position as a trusted partner for veterinarians, water quality professionals, and livestock producers worldwide. IDEXX employs approximately 11,000 people.

What Products and Services Does IDXX Offer?

• Develops and manufactures diagnostic products for companion animals.
• Provides reference laboratory diagnostic and consulting services.
• Offers practice management and diagnostic imaging systems for veterinarians.
• Develops health monitoring and biological materials testing for biomedical research.
• Provides diagnostic and health-monitoring products for livestock, poultry, and dairy.
• Offers products that test water for microbiological contaminants.
• Provides veterinary software and services for independent veterinary clinics and corporate groups.

How Does IDXX Make Money?

• Sales of point-of-care veterinary diagnostic products, including instruments and consumables.
• Revenue from veterinary reference laboratory diagnostic and consulting services.
• Sales of water quality testing products.
• Subscription fees for practice management software and services.

What Industry Does IDXX Operate In?

IDEXX Laboratories operates in the growing veterinary diagnostics and water quality testing markets. The veterinary diagnostics market is driven by increasing pet ownership, rising pet healthcare spending, and advancements in diagnostic technologies. The water quality testing market is fueled by stringent regulations and growing concerns about waterborne diseases. IDEXX competes with companies like Becton, Dickinson and Company (BDX) and Zoetis Inc. (ZTS), but its comprehensive product portfolio and global reach provide a competitive advantage. The industry is expected to continue growing at a steady pace, driven by increasing awareness of animal health and water safety.

Who Are IDXX's Key Customers?

• Companion animal veterinarians.
• Livestock, poultry, and dairy producers.
• Water quality professionals.
• Biomedical research institutions.

Net buyingInsider Activity

Over the past six months, IDEXX Laboratories, Inc. insiders filed 15 SEC Form 4 transactions — 2 sales and 13 purchases. On net that is roughly 4K shares acquired (about $1.3M) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: IDEXX Laboratories, Inc.

Revenue for IDEXX Laboratories, Inc. came in at $1.14B during Q1 2026, a 4.6% improvement versus the preceding quarter. The company recorded net income of $278.4M, with diluted EPS of $3.45. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, IDXX averaged $3.39 in diluted EPS.

IDXX Valuation & Market Position

With a $43.0B market cap, IDEXX Laboratories, Inc. sits in the large-cap segment of the market. Relative to its peer group, IDXX's quantitative score of 93/100 is above the peer average of 76/100.

ROE 71%Key Financial Metrics

Return on equity for IDEXX Laboratories, Inc. stands at 70.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 32.4%, showing how much profit it generates from its asset base. IDXX trades at a trailing price-to-earnings ratio of 38.50, above the Healthcare sector average of ~23x. Its free cash flow yield is 2.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.12 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 8/9Financial Health

IDEXX Laboratories, Inc.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 19.79 places it in the safe zone, indicating low near-term bankruptcy risk.

8/8 beatsEarnings Track Record

IDEXX Laboratories, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 6.1% above estimates on average.

FY2026 estForward Outlook

Wall Street analysts project IDEXX Laboratories, Inc. revenue of about $4.71B for fiscal 2026, with EPS near $14.65. The estimate reflects 11 contributing analysts.

Company Profile

IDEXX Laboratories, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Westbrook, US. The company is led by CEO Michael Erickson. IDXX has traded publicly since 1991.

IDXX Financials

IDXX Latest News

IDXX Analyst Consensus

IDXX MoonshotScore

IDEXX Laboratories, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources